PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 999818-6 1976 The conncentrations of drug necessary to inhibit thymidine and uridine uptake into HeLa cells by 50% are 10 and 5 muM, respectively, for podophyllotoxin, and 25 and 20 muM for VP-16-213. Etoposide 176-181 latexin Homo sapiens 168-171 26988802-9 2016 Further evaluation of endogenous topo-mediated DNA relaxation in cells has been conducted to find that, 5d inhibited endogenous topo-mediated pBR322 plasmid relaxation is more efficient (78.0 +- 4.7% at 50 muM) than Etoposide (36.0 +- 1.7% at 50 muM). Etoposide 216-225 latexin Homo sapiens 206-209 31030314-3 2020 They exhibited better cytostatic effects than etoposide (GI50 = 0.56-36.62 muM), parthenolide (GI50 = 3.58-25.97 muM) and VK3 (GI50 = 3.41-22.59 muM) against several of the cancer cell lines. Etoposide 46-55 latexin Homo sapiens 75-78 31374424-3 2019 These results exhibited more effectivity than anticancer agent etoposide (35muM) and merbarone (40-50muM). Etoposide 63-72 latexin Homo sapiens 76-79 31106192-3 2019 In particular, compound 12h showed high activity with IC50 values ranging from 1.2 to 22.8 muM, with much better cytotoxic activity than the control drug etoposide (IC50: 8.4 to 78.2 muM). Etoposide 154-163 latexin Homo sapiens 183-186 27852227-9 2016 The combinatorial, but not separate, treatment with low doses of 5-aza-2"-deoxycytidine (0.1 muM) and etoposide (0.5 muM) caused a long-lasting (almost 70 days) reduction in clonogenic/replating ability of DLD-1 cells. Etoposide 102-111 latexin Homo sapiens 117-120 27707625-5 2016 Compounds 9, 11, and 13 inhibited the function of topoisomerase II more strongly than etoposide with almost same magnitude (around 90% and 30% inhibition at 100 and 20muM, respectively) which were higher than those of etoposide (72% and 18% inhibition). Etoposide 86-95 latexin Homo sapiens 167-170 25709376-3 2014 Significantly, compound 17h showed superior cytotoxic activity compared with etoposide (IC50 6.30 to>10 muM), a clinically available anticancer drug. Etoposide 77-86 latexin Homo sapiens 107-110 26361737-3 2015 Compounds 10a, 10g, 11a, 11f, 11g, 12a, 12f, and 12g especially showed stronger topoisomerase II inhibitory activity as compared to etoposide at both 100 muM and 20 muM. Etoposide 132-141 latexin Homo sapiens 165-168 25592050-5 2015 Etoposide levels of 10 muM were found to maximise toxicity to tumours (6.5% viability) while stem cells maintained a surviving fraction of 40%. Etoposide 0-9 latexin Homo sapiens 23-26 26154885-3 2015 Most of the derivatives (IC50 = 1-20 muM) were found to have stronger cell growth inhibitory activity than positive control etoposide. Etoposide 124-133 latexin Homo sapiens 37-40 25618019-7 2015 OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively. Etoposide 169-178 latexin Homo sapiens 203-206 25618019-7 2015 OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively. Etoposide 169-178 latexin Homo sapiens 212-215 25618019-7 2015 OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively. Etoposide 169-178 latexin Homo sapiens 212-215 25618019-7 2015 OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively. Etoposide 169-178 latexin Homo sapiens 212-215 25618019-7 2015 OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively. Etoposide 169-178 latexin Homo sapiens 212-215 25618019-7 2015 OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively. Etoposide 169-178 latexin Homo sapiens 212-215 25690288-3 2015 Among the synthesized compounds, compound 21a shows the highest activity, with IC50 values ranging from 0.49 to 6.70 muM, which is more potent than the control drugs etoposide and cisplatin. Etoposide 166-175 latexin Homo sapiens 117-120 26000396-4 2014 The percent inhibition in case of ETP and ETP: CUR (1:3 w/w) was 55.92 +- 1.2 and 41.13 +- 2.4% (at 5 muM) respectively when tested in PC3 cells. Etoposide 34-37 latexin Homo sapiens 102-105 26000396-4 2014 The percent inhibition in case of ETP and ETP: CUR (1:3 w/w) was 55.92 +- 1.2 and 41.13 +- 2.4% (at 5 muM) respectively when tested in PC3 cells. Etoposide 42-45 latexin Homo sapiens 102-105 26000396-6 2014 Our data shows that CUR and ETP after encapsulation in nanoemulsion (F5) were effectively delivered intracellularly in PC3 cells and the cytotoxicity of F5 was enhanced by 1.5 fold as compared to ETP + CUR at 5 muM concentration. Etoposide 28-31 latexin Homo sapiens 211-214 24232736-4 2013 Among them, compound 35 showed the highest potency against all five cancer cell lines tested, with IC50 values ranging from 0.59 to 2.90 muM, which is significantly more active than the drug etoposide currently in clinical use. Etoposide 191-200 latexin Homo sapiens 137-140 24553146-4 2014 Among the new analogs, compounds 12e (IC50: 0.60-0.75 muM) and 12h (IC50: 1.12-2.03 muM) showed superior potency to etoposide (IC50: 2.03 to >20 muM), a clinically available anticancer drug. Etoposide 116-125 latexin Homo sapiens 54-57 24553146-4 2014 Among the new analogs, compounds 12e (IC50: 0.60-0.75 muM) and 12h (IC50: 1.12-2.03 muM) showed superior potency to etoposide (IC50: 2.03 to >20 muM), a clinically available anticancer drug. Etoposide 116-125 latexin Homo sapiens 84-87 24553146-4 2014 Among the new analogs, compounds 12e (IC50: 0.60-0.75 muM) and 12h (IC50: 1.12-2.03 muM) showed superior potency to etoposide (IC50: 2.03 to >20 muM), a clinically available anticancer drug. Etoposide 116-125 latexin Homo sapiens 84-87 24055188-6 2013 Interestingly in HepG2 cells, resveratrol exhibited the same levels of cytotoxicity as etoposide (10 muM) when the cells treated with >= 25 muM for 48-72 h. In contrast to HepG2, resveratrol significantly enhanced anti-proliferative effects of etoposide in HCT-116 cells. Etoposide 87-96 latexin Homo sapiens 101-104 24055188-6 2013 Interestingly in HepG2 cells, resveratrol exhibited the same levels of cytotoxicity as etoposide (10 muM) when the cells treated with >= 25 muM for 48-72 h. In contrast to HepG2, resveratrol significantly enhanced anti-proliferative effects of etoposide in HCT-116 cells. Etoposide 87-96 latexin Homo sapiens 143-146 23698047-6 2013 The best antiproliferative effect against HL-60 cells was found for compounds 3 and 17, with IC50 values of 22.3 and 23.2 muM, lower than that found for the reference compound etoposide (2.23 muM). Etoposide 176-185 latexin Homo sapiens 192-195 23879966-9 2013 Pre-incubation of VPA17 cells in 30 muM silibinin for 5 days also reversed resistance to etoposide (IC50 = 5.50 to 0.65 muM) and doxorubicin (IC50 = 0.625 to 0.035 muM). Etoposide 89-98 latexin Homo sapiens 36-39 23879966-9 2013 Pre-incubation of VPA17 cells in 30 muM silibinin for 5 days also reversed resistance to etoposide (IC50 = 5.50 to 0.65 muM) and doxorubicin (IC50 = 0.625 to 0.035 muM). Etoposide 89-98 latexin Homo sapiens 120-123 23879966-9 2013 Pre-incubation of VPA17 cells in 30 muM silibinin for 5 days also reversed resistance to etoposide (IC50 = 5.50 to 0.65 muM) and doxorubicin (IC50 = 0.625 to 0.035 muM). Etoposide 89-98 latexin Homo sapiens 120-123 23146242-7 2013 Frontal displacement experiments with multiple concentrations of etoposide were run and the binding affinity was determined to be 4.54 muM, which is in close agreement with literature. Etoposide 65-74 latexin Homo sapiens 135-138 22182671-7 2012 Even though both types of RB cells express TRPV1 as well as TRPM8 and CB1, the capsaicin (50 muM) (CAP)-induced Ca(2+) rise caused by TRPV1 activation was prompt and transient only in etoposide-resistant RB cells (n = 8). Etoposide 184-193 latexin Homo sapiens 93-96 23248400-7 2012 However, low dose (10 muM) or IC50 (70 muM) Eto doses showed G2/M or S-phase arrests, respectively (P<0.001). Etoposide 44-47 latexin Homo sapiens 39-42 23248400-9 2012 Moreover, Eto (10 muM) led to decreased percent of cells in G2/M phase when combined with LiCl (P<0.05). Etoposide 10-13 latexin Homo sapiens 18-21 21905773-8 2011 RESULTS: Vincristine, doxorubicin, etoposide, cisplatin, and fludarabine, each at a concentration of 10 muM, decreased the number of chordoma cells when given alone down to 11%, 0%, 30%, 67%, and 3%, respectively. Etoposide 35-44 latexin Homo sapiens 104-107 21905773-9 2011 Etoposide and cisplatin, each at a concentration of 10 muM, reduced the percentage of viable chordoma cells in a more effective way when given with 1 muM ATRA simultaneously, reducing the number of viable cells to 14% and 9%, respectively. Etoposide 0-9 latexin Homo sapiens 55-58 21905773-9 2011 Etoposide and cisplatin, each at a concentration of 10 muM, reduced the percentage of viable chordoma cells in a more effective way when given with 1 muM ATRA simultaneously, reducing the number of viable cells to 14% and 9%, respectively. Etoposide 0-9 latexin Homo sapiens 150-153 21896713-4 2011 We imposed cellular stress by starvation or administration of etoposide (0.5-50 muM), sorafenib (1-40 muM), staurosporine (20-500 nM), or thapsigargin (20-500 nM) (1, 2, or 3 h) and measured the formation of WIPI-1 positive autophagosomal membranes. Etoposide 62-71 latexin Homo sapiens 80-83